Statement: Two dozen the primary trial participants are classified as having Pathologic Complete Response (pCR) in the Breast and Nodes.
Primary_evidence: Outcome Measurement:    Number of Participants With Pathologic Complete Response (pCR) in the Breast and Nodes   pCR was defined as no histologic evidence of invasive tumor cells in the surgical breast specimen, axillary nodes, or sentinel node identified after neoadjuvant chemotherapy.   Time frame: From the start of the study until the time of surgery (average of 221.9 days [standard deviation of 23.65 days] after study entry) Results 1:    Arm/Group Title: AC, Followed by Weekly Paclitaxel and Concurrent Pazopanib   Arm/Group Description: Participants were treated with intravenous (IV) doxorubicin (60 milligrams per meters squared [mg/m^2]) and cyclophosphamide (AC) (600 mg/m^2) every 21 days for 4 cycles. This was followed by weekly paclitaxel (WP) 80 mg/m^2 IV on Days 1, 8, and 15 every 28 days for 4 cycles given concurrently with oral pazopanib 800 mg (2 tablets taken at the same time each day, either 1 hour before or 2 hours after a meal) taken daily and continuing until 7 days before surgery. Pazopanib was resumed at the same oral dose 4-6 weeks after surgery and was continued daily for 6 months.   Overall Number of Participants Analyzed: 93   Measure Type: Number   Unit of Measure: Participants  16